Albumedix and Valneva Expand Collaboration to Include Newly Approved Inactivated COVID-19 Vaccine

USA - English

• USA - Français
• USA - Deutsch
• USA - español

NOTTINGHAM, England, April 14, 2022 /PRNewswire/ -- Valneva's inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14^th. This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin® rHA products in the manufacturing process and final formulation of critical vaccines. 

Albumedix Ltd. (´Albumedix´), a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE (´Valneva´), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.  

This announcement comes on the back of the recent approval of Valneva´s inactivated COVID-19 vaccine (VLA2001) by MHRA, for which Valneva signed an agreement in November 2021 with the European Commission to supply up to 60 million doses over 2 years, as well as announcing an advance purchase agreement with the Kingdom of Bahrain in December 2021 for the supply of one million doses.  

Albumedix Recombumin® rHA is an essential component in VLA2001, used in the manufacturing process and final formulation of the vaccine. The companies began their collaboration with the inclusion of Recombumin® in Valneva's single-shot vaccine candidate against the mosquito-borne viral infection chikungunya, VLA1553, which successfully completed its pivotal Phase 3 trial in March 2022. Both companies are committed to producing safe, effective and scalable vaccines.  

Albumedix´ Chief Executive Officer, Jonas Skjødt Møller, reflects on the announcement; "We are excited to expand our relationship with a valued partner like Valneva, thereby continuing to leverage our long track record of supporting vaccine companies in their development of safe and scalable vaccines. In the last 2 years, it has been incredible to witness and partake in the monumental achievements realized by the life science industry through purpose-led collaborations like the one we share with Valneva."  

Valneva's Chief Operating Officer, Vincent Dequenne, added; "We wholeheartedly welcome the contribution that Albumedix is making to the manufacture of our newly approved inactivated, whole virus COVID-19 vaccine – the first of its kind developed in Europe. Our collaboration is enabling the development of vaccines to address significant unmet medical need, including this differentiated COVID-19 vaccine option for populations and physicians who need it."  

Albumin is an established enabler of advanced therapies and biopharmaceuticals and the properties of Recombumin® are shown to be beneficial across a broad range of vaccine modalities. Consequently, Albumedix´ rHA´s are already included in a range of vaccine candidates in clinical development and marketed vaccines, resulting in more than 210 million safe injections with Recombumin®. 

About: 

For further information about Albumedix or Recombumin®, please visit Albumedix website: www.albumedix.com  

For further information about Valneva or VLA2001, please visit Valneva´s website: www.valneva.com 

For media enquiries, please contact:  

Poula Maltha Krogh, Director of Market Development & Communication, [email protected]   

Photo - https://mma.prnewswire.com/media/1797317/Albumedix_Valneva.jpg

SOURCE Albumedix Ltd.